🇺🇸 FDA
Patent

US 10093629

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

granted A61KA61K31/4375A61K31/472

Quick answer

US patent 10093629 (Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/4375, A61K31/472, A61K31/4741, A61P